Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
33.7 EUR | +0.60% | +6.98% | -20.41% |
Apr. 04 | DERMAPHARM : Berenberg keeps its Buy rating | ZD |
Mar. 28 | Dermapharm Holding SE Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The company has a low valuation given the cash flows generated by its activity.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The group shows a rather high level of debt in proportion to its EBITDA.
- The company appears highly valued given the size of its balance sheet.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-20.41% | 1.94B | B- | ||
+31.52% | 662B | C+ | ||
+21.96% | 546B | B | ||
-5.21% | 359B | C+ | ||
+17.02% | 323B | B- | ||
+5.01% | 289B | C+ | ||
+13.68% | 234B | B+ | ||
+3.81% | 198B | B- | ||
-10.63% | 194B | A+ | ||
+3.98% | 167B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- DMP Stock
- Ratings Dermapharm Holding SE